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Abstract
The bcl -2 and c -myc oncogenes cooperate to transform
multiple cell types. In the pediatric malignancy NB2, Bcl-
2 is highly expressed. In tumors with a poor prognosis,
N-Myc, a protein homologous to c-Myc, is overex-
pressed as a result of gene amplification. The present
study was designed to determine whether Bcl-2 coop-
erates with N-Myc to bestow a tumorigenic phenotype to
neuroblastoma (NB) cells. NB cell lines that at baseline
express neither Bcl-2 nor N-Mycwere stably transfected
to express these gene products. In this model, we found
Bcl-2 rescues N-Myc–expressing cells from apoptosis
induced by serum withdrawal. Coexpression of Bcl-2
and N-Myc supports growth in low serum conditions
and anchorage- independent growth in soft agar. Sim-
ilarly, in vivo tumorigenic and angiogenic activity was
dependent on coexpression. Our data further suggests
that the mechanism underlying these changes involves
the receptor for insulin growth factor type I ( IGF-IR).
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Introduction
Neuroblastoma (NB) is the most common extracranial solid
tumor of children accounting for 10% of all childhood
cancers [1 ]. The disease arises from sympathetic neuro-
blasts. Although the molecular defect(s) responsible for the
genesis of NB is unknown, several biologic markers have
been identified that correlate with disease outcome. N-myc
gene amplification is the single best predictor of aggressive
tumor growth and poor treatment outcome [2], implying this
gene has an important role in pathogenesis. Nevertheless,
N-myc’s molecular role in NB tumor behavior remains ill
defined. N-Myc overexpression by single gene transfection
advances the malignant phenotype of some human NB cells
lines [3]. However, N-Myc overexpression also induces a
predisposition to apoptosis in serum-deprived conditions [4].
The transforming and tumorigenic potential of the relatedmyc
family member, c-myc [5 ] depends on coexpression with
bcl -2 in hematopoietic and fibroblastic cell types [6–8]. As
such it is plausible that N-myc’s oncogenic activity in NB
requires the cooperation of other gene products, possibly
Bcl -2.
Bcl -2 protein is detected in 40% to 100% of primary NB
tumors and cell lines [9–11]. We and others have shown
that in untreated human NB tumors, Bcl -2 expression
correlates with N-myc amplification and unfavorable histol-
ogy [9,12]. High levels of Bcl -2 are detected in residual
tumor cells from patients who have persistent or recurrent
disease following chemotherapy [9,13]. Targeted over-
expression of Bcl -2 in NB cell lines decreases sensitivity
to cytotoxic agents [14], further supporting a role in
chemotherapy resistance.
A substantial fraction of NB tumors and cell lines
overexpress N-Myc in the context of detectable Bcl -2.
The behavior of NB tumors expressing both gene products
might differ from those expressing either one or the other.
Understanding whether these genes act cooperatively such
that the oncogenic activity of one depends on the other
would provide a further basis to stratify disease risk.
Cooperative interplay has been observed between the N-
myc–related genes c-myc and N-myc2 in hematopoietic
and murine hepatic cells, respectively [4,6–8]. We
hypothesized that Bcl -2 expression facilitates N-Myc–
induced transformation of NB cells. To test this hypothesis
we stably transfected two human NB cell lines (SH-EP1
and SK-N-AS), which at baseline do not express
detectable amounts of either Bcl -2 or N-Myc. Coexpres-
sion of Bcl -2 and N-Myc sustained growth in reduced
serum, supported anchorage- independent growth and
enhanced both angiogenic activity and in vivo tumori-
genesis. Coexpression was associated with high- level
insulin growth factor receptor type 1 ( IGF-IR) expression
further implicating this receptor system in the transformed
phenotype of NB and providing mechanistic insight about
the cooperative mechanism.
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Materials and Methods
Cell Lines
The NB cell lines SMS-KCNR, SH-EP1, and SK-N-AS
[15–17] were used in this study. SH-EP1 and SK-N-AS
cell lines do not express detectable levels of Bcl -2 or N-
Myc by Western analysis (Castle, unpublished observa-
tions). The SMS-KCNR NB line is N-myc amplified,
expresses Bcl -2 and is tumorigenic in xenograft models.
An NIH-3T3 cell line transformed by v-src was used as a
positive control in soft agar assays. Cells were maintained
in minimum essential medium (MEM) or RPMI-1640
(Sigma-Aldrich, St. Louis, MO) supplemented with 10%
fetal bovine serum (FBS), 2 mM glutamine, 10 U/ml
penicillin and 100 g/ml streptomycin. Following trans-
fection, cells were cultured in the same medium supple-
mented with G418 (Life Technologies, Rockland, MD) at
500 g/ml.
Transfections
The SH-EP1 and SK-N-AS lines were stably transfected
to generate four expression phenotypes: Bcl -2 alone, N-
Myc alone, Bcl -2 /N-Myc, or vector control. Expression
plasmids used for these studies were pSSFVneo-bcl -2;
vector pSSFVneo [18] (gift of Gabriel Nun˜ez, University of
Michigan); pCMV-N-myc and vector pSMneo [19 ] (gift of
William Fahl, McArdle Laboratory for Cancer Research,
Madison WI). Clones designated vector control were
simultaneously transfected with both empty vector plasmids.
Transfections were performed using lipofectamine according
to the manufacturer instructions (Gibco, Grand Island, NY).
Briefly, 5104 cells were plated in serum-free medium and
transfected with 10 g of plasmid DNA. Forty -eight hours
later, cells were transferred to 100-mm plates and selected
in G418. G418-resistant colonies were transferred by filter
paper and subcultured individually. The resulting G418-
resistant colonies expressed variable levels of both Bcl -2
and N-Myc protein. The clones chosen for further study
expressed the highest levels of both proteins, similar to the
control KCNR cell line.
Detection of Bcl -2, N-Myc, and IGF-IR by Western
Analysis
The expression of Bcl -2, N-Myc, and IGF-IR was
determined by Western analysis using the enhanced
chemiluminescence technique (ECL detection kit, Amer-
sham International, Buckinghamshire, UK). Cells were
harvested and lysed in a buffer containing 50 mM Tris–
HCL, 100 mM dithiothreitol, 2% SDS, 0.1% bromphenol blue,
and 10% glycerol. Protein was quantified using a Bradford
assay (BioRad Laboratories, Hercules, CA). Protein was
electophoretically resolved on 12% SDS–polyacrylamide
gels and transferred to nitrocellulose by electroblotting.
Proteins were detected with either hamster monoclonal
antibody to N-Myc (AB-1, Oncogene Science, San Diego,
CA), a polyclonal antibody to Bcl -2 (6C8, Pharmingen, San
Diego, CA), a polyclonal antibody to IGF- IR (Santa Cruz
Biotechnology, Santa Cruz, CA) or a monoclonal antibody
for glyceride-3-phosphate dehydrogenase (GAPDH,
Chemicon, Temacula, CA).
Cell Growth and Viability
Cells (5104) were suspended in growth medium
containing 1% FBS in wells on 96-well plates. Growth
medium was replaced every other day for the duration of the
experiment. Cell viability and number was assessed using
the MTT assay [20] using a lysis buffer containing 2% SDS,
50% N,N -dimethylformamide (pH 4.5). Absorbance at 570
nM (Abs570 ) was determined for each well using an ELX
808 automated microplate reader (Bioteck Instruments,
Winnoski, VT). After subtracting for background absorb-
ance of the medium, the viability of each cell line was
expressed as the viable cell index [VCI=(Abs570 on
consecutive days/Abs570 on day 0)100]. Data is pre-
sented as the mean and standard deviation (SD) of multiple
experiments.
Independent Colony Growth in Soft Agar
Cells (104) were plated in triplicate in 2 ml of 0.33% low
melting point agarose (Seaplaque, FMC, Rockland, ME) in
MEM containing 10% FBS, 2 mM glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin, over 0.9% bottom
agar plates prepared in the same medium. Plates were
incubated at 378C in a humidified 5% CO2 incubator. Foci
were scored as colonies if the collection of cells could be
visualized without microscopic aid 14 days after plating.
Tumorigenicity in Athymic Mice
In vivo growth of tumor cells was determined in female
Swiss athymic mice (Charles River Laboratories, Raleigh,
NC) as previously described [21]. After routine culture, cells
were harvested by trypsinization and suspended in a total
volume of 100 l with serum-free MEM. The cell suspension
was injected into the anterior thigh musculature. Mice were
observed three times per week over 90 days to detect tumors
and volumes estimated on the basis of two dimensions as
previously reported [22]. After sacrifice, tissue was prepared
for histologic analysis.
Quantification of Microvessels in Tumor Specimens
Microvessels were identified in tissue sections by
immunostaining for endothelial cells with antimouse
PECAM-1 (CD31). Formalin - fixed, paraffin-embedded
tissues mounted on glass slides were deparaffinized and
quenched in 0.3% H2O2 in methanol to block endogenous
peroxidase. Antigen retrieval was accomplished by heating
tissue sections in citrate buffer (pH 6.0) for 10 minutes and
placing sections in a 1100-W microwave oven on full
power for an additional 10 minutes. Sections were cooled
to room temperature, washed with buffer and incubated
with normal mouse serum (1:200) for 30 minutes. Slides
were incubated with primary antibody (rabbit antimouse
CD31, 1:10, Dako, Carpinteria, CA) overnight at 378C, then
with secondary antibody (biotinylated goat antirabbit IgG,
1:500) for 30 minutes, followed by a 30-minute incubation
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with avidin–biotin–horseradish peroxidase complex (ABC,
Vector Laboratories, Burlingame, CA). Color development
was done with 3-amino 9-ethyl carbazole treatment
followed by counterstain with Gill’s hematoxylin. As a
negative control, sections were treated with secondary
antibody alone. Microvessels were quantitated by a
modification of the method of Weidner et al. [23 ]. Sections
were examined under low magnification to identify the
regions of highest vessel density and the vessel counts in
each of 10 high power fields (HPF) (400 ) were
determined. A vessel lumen was not required for identi-
fication of a microvessel; cell clusters were counted. Vessel
counts were obtained from a minimum of three different
sections per tumor and expressed as the mean number per
10 HPF.
Assessment of Angiogenic Activity in Conditioned Medium
The rat micropocket assay was used to assess angio-
genic activity of conditioned medium as previously described
[24]. Conditioned medium was concentrated 5- to 10- fold
using Centricon spin columns (3000 MW, Millipore, Bedford,
MA) to a protein concentration of 1 g/5 l. Equal volumes of
concentrated medium and Hydron casting solution were
combined. Ten microliters of the resulting solution was
dispensed atop the surface of 1-mm-diameter Teflon rods
(Dupont, Wilmington, DE) and air -dried in a laminar flow
hood. Dried pellets were rehydrated with phosphate-
buffered saline and implanted into surgically created pockets
in the eyes of Fisher strain rats. Animals were examined daily
to monitor vessel response. After 7 days, rats were perfused
with colloidal carbon to enumerate new corneal vessels.
After enucleation, corneas were excised, fixed in 10%
formalin, and photographed. Positive neovascular
responses were recorded when a brush- like network of
capillary sprouts and hairpin loops were observed extending
from the limbus toward the implant. Negative responses
were recorded if only an occasional capillary sprout with no
evidence of sustained growth was observed or when no
growth was detected. Corneal responses were quantified by
measuring the area occupied by new capillaries and venules
using NIH Image software. Corneal mounts were photo-
graphed and digitized into Adobe PhotoShop 5.0. The area
occupied by new vessels was captured with NIH Image and
the results were expressed as the area in pixels. At least
three corneas were evaluated per cell line and the results
shown as mean values with standard deviation.
Statistics
The Fisher’s exact test was used to determine statistical
significance unless otherwise indicated.
Results
Generation of Bcl -2– and N-Myc–Expressing NB Cell
Lines
To determine whether Bcl -2 cooperates with N-Myc to
enhance the tumorigenicity of NB, two NB cell lines (SH-
EP1 and SK-N-AS) were stably transfected to express Bcl -
2, N-Myc, or both gene products. Whereas the SH-EP1 and
SK-N-AS lines express no detectable Bcl -2 or N-Myc at
baseline, multiple unique transfectants were found that
express levels of Bcl -2 and N-Myc comparable to the
control SMS-KCNR NB cell line (Figure 1 ).
Bcl-2 and N-Myc Coexpression Confers Serum- and
Anchorage- Independent Growth Characteristics
SH-EP1 and SK-N-AS cells expressing Bcl -2, N-Myc,
or both gene products were cultured in reduced serum
media. Under these conditions, neither parental line was
able to proliferate (Figure 2 ). Transfectants expressing
only Bcl -2 similarly had no proliferative capacity. N-Myc
expression in SK-N-AS cells resulted in cell death
evidenced by a decrease in cell number after 2 to 6
days. Even though the viability of N-Myc–expressing SH-
Figure 1. Immunoblot analysis of SH -EP1 and SK -N -AS transfectants for
Bcl - 2 and N-Myc expression. The Bcl - 2 and N-My–expressing SMS-
KCNR cell line was used as a positive control. Equivalent protein loading is
confirmed by GAPDH detection.
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EP1 cells did not similarly decrease in low serum, TUNEL
revealed increased apoptosis in both SH-EP1 and SK-N-
AS cells overexpressing N-Myc when compared to vector
controls (data not shown). Most dramatically, coexpres-
sion of Bcl -2 and N-Myc ( in multiple unique clones)
provides each parental cell type the ability to proliferate in
serum deprived culture conditions.
Anchorage- independent growth was observed only in
those transfectants that coexpressed Bcl -2 and N-Myc
(Figure 3, Table 1). Vector control lines or SH-EP1 and SK-
N-AS cells expressing Bcl -2 or N-Myc alone did not grow in
soft agar. All transfected clones coexpressing Bcl -2 and N-
Myc produced soft agar colonies at a plating efficiency that
approached that of the highly transformed v-src NIH-3T3
positive control line.
Bcl-2 and N-Myc Cooperate to Induce Tumors in Animals
We tested the transfected cell lines to determine
tumorgenic potential in a mouse xenograft model. Cells
of each transfectant [ (1 and 2)107] as well as the SMS-
KCNR positive control line were inoculated into athymic
mice (Figure 4A ). All animals inoculated with either dose of
SMS-KCNR control cells formed palpable tumors within 26
days. In contrast, SH-EP1 and SK-N-AS vector control
lines formed no tumors during the experimental course (90
days). Similarly, SH-EP1 cells expressing either Bcl -2 or
N-Myc formed no tumors. However, cells expressing both
Bcl -2 and N-Myc were tumorigenic with the take rate
increasing with inoculated cell number. Thirty- three per-
cent of mice receiving 1107 cells formed tumors whereas
65% injected with 2107 cells formed tumors. SK-N-AS
cells transfected to express Bcl -2, N-Myc, or the two
together also formed tumors. At the lower inoculum (1107
cells ) 100% of mice injected with SK-N-AS Bcl -2 /N-Myc
cells formed tumors as compared with 33% injected with
the same inoculum of SH-EP1 Bcl -2 /N-Myc–expressing
cells (P<.001).
The growth characteristics of the SK-N-AS Bcl -2
tumors were significantly different from the SK-N-AS N-
Myc and SK-N-AS Bcl -2 /N-Myc tumors: the latency to
tumor formation was 61 days vs 13 to 27 days and the
time to triple 74 days vs 25 to 33 days (P<.05). The
growth characteristics of the SH-EP1 Bcl -2 /N-Myc lines
were similar to the SK-N-AS Bcl -2 line. The SH-EP1
Bcl-2/N-Myc tumors were recognized after 54 to 78 days
and tripled in size by 72 days. There was a statistically
significant difference in take rate, latency, and time to
triple between the SH-EP1 Bcl -2 /N-Myc and SK-N-AS
Bcl-2/N-Myc lines (P<.001). These results suggest Bcl -
2 and N-Myc cooperate to enhance the tumorigenicity of
NB cells. However, the impact of coexpression on in vivo
growth characteristics varies between parental cell types
suggesting other factors influence this cooperative inter-
play.
Histologic Analysis of Xenograft Tumors
The histologic appearance of the SH-EP1 and SK-N-
AS tumors was similar (Figure 4B ). As well, there were
no distinguishing features between Bcl -2 /N-Myc, Bcl -2
alone, or N-Myc alone tumors. All tumors had a biphasic
phenotype. They were variably necrotic with morphologic
features of sarcomatous and chondroblastic differentiation.
Some tumors showed hyperchromatic background cells
with limited amounts of amphophilic cytoplasm, round to
oval nuclei and prominent eosinophilic, and generally
single nucleoli. Abnormal mitotic figures were abundant.
The more epithelial appearing areas included cells with
abundant eosinophilic cytoplasm and variable shape.
Unlike human NB tumor specimens, tumors from the
transfectants showed no neuropile, rosetting, or stroma
formation.
Tumor Microvasculature and Angiogenic Activity
Tumor microvasculature was examined to determine if
angiogenic activity correlates with the differences in tumor-
igenicity observed between the SH-EP1 and SK-N-AS
transfectants. The greatest angiogenic response was seen in
S-K-AS Bcl-2 /N-Myc tumors (Figure 5 ). Vessel counts in
these tumors were similar to counts in positive control SMS-
KCNR tumors. Tumors from SK-N-AS Bcl -2 and SK-N-AS
N-Myc single transfectants had approximately 50% as many
vessels as SK-N-AS Bcl -2 /N-Myc tumors. Vessel counts
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Figure 2. Relative viability after culture in medium with 1% serum was
determined by MTT for (A ) SK -N -AS and (B ) SH-EP1 transfectants. Data
presented as the mean and standard deviation from three separate
experiments.
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from SH-EP1 Bcl -2 /N-Myc tumors were significantly lower
than the SK-N-AS Bcl-2 /N-Myc counterparts (P<.001).
To further extend the evaluation of angiogenic activity to
include the transfected lines that did not produce tumors
(SH-EP1 Bcl -2 and SH-EP1 N-Myc), in vitro angiogenic
activity was assessed in rat corneas. Vector - transfected
controls failed to induce a neovascular response (Figure 6, A
and C ). SH-EP1 Bcl-2 /N-Myc and SK-N-AS Bcl -2 /N-
Myc lines induced a response (Figure 6, A and B ).
Neovascularization was established as early as 3 days after
pellet implantation with further growth and recruitment of
additional new capillaries throughout the 7-day assay
period. Significant neovascular responses were also
detected from each of the single gene transfectants. The
responses from each of these cell types were nearly
equivalent and significantly less than that observed for cells
expressing both Bcl -2 and N-Myc. These results are most
consistent with Bcl -2 and N-Myc independently increasing
angiogenic activity, although their coexpression results in an
additive response. In vitro angiogenic activity does not
predict tumorigenic behavior because the nontumorigenic
SH-EP1 single gene transfectants induced an angiogenic
response equivalent to their tumorigenic SK-N-AS counter-
parts.
Bcl-2 and N-Myc Increase IGF- IR Expression
To understand the process by which coexpression
enhanced the transformation of NB cells (acquisition of
serum and anchorage- independent growth, tumorigenicity )
we examined the effects on the IGF- IR signaling pathway
(Figure 7 ). IGF- IR was chosen, as it is known to support
the growth and chemotaxis of NB cells [25–27]. IGF- IR
expression was undetectable in SH-EP1 vector–trans-
fected and SH-EP1 Bcl-2–expressing lines. SH-EP1
cells expressing N-Myc alone show slight IGF-IR expres-
sion. However, SH-EP1 cells expressing Bcl -2 /N-Myc
show substantial IGF-IR expression. In contrast to SH-
EP1 cells, SK-N-AS vector controls express some ( low
basal level ) IGF-IR. IGF-IR is increased in SK-N-AS
cells expressing only Bcl -2, only N-Myc, and in cells
expressing both Bcl -2 and N-Myc. These data suggest a
relationship between induced IGF-IR expression and
tumorigenicity. Each of the tumorigenic clones expressed
IGF- IR. IGF-IR is dramatically induced in SH-EP1 cells
when Bcl -2 and N-Myc are coexpressed reflecting the
cooperative action of these gene products. As presented
above, cooperation was also necessary for tumorigenesis
in SH-EP1 cells. In SK-N-AS cells, either Bcl -2 or N-Myc
induces IGF-IR without any further increase caused by
coexpression. Similar to these findings, cooperativity
Table 1. Anchorage - Independent Soft Agar Colony Formation.
Parental Cell Line Clone Colonies*
NIH -3T3 v - src 1000
vector 0
SH-EP1 N-Myc 0
Bcl - 2 5
Bcl - 2 /N -Myc #1 471
Bcl - 2 /N -Myc #2 420
vector 0
SK -N -AS N-Myc 0
Bcl - 2 0
Bcl - 2 /N -Myc #1 580
Bcl - 2 /N -Myc #2 450
*Colonies per 104 plated cells. Average of three replicate experiments.
Figure 3. Soft agar growth observed under 10magnification of foci from (A ) SH -EP1 vector, (B ) SK -N -AS N-Myc, (C ) SH-EP1 Bcl - 2 /N -Myc and (D ) SK -N -
AS Bcl - 2 /N -Myc.
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appeared to play a minor role in the tumorigenic behavior
of SK-N-AS cells.
Discussion
The capacity of bcl -2 to cooperate with c-myc to enhance
tumor growth is established in lymphoma and mammary
carcinoma [28,29]. We hypothesized that a similar cooper-
ative relationship exists between bcl -2 and N-myc. NB
provides an important model to assess whether cooperation
between bcl -2 and N-myc contributes to oncogenesis,
because NB tumor specimens and cell lines commonly
express both of these genes [9,12,30]. In NB, it is well known
that N-Myc overexpression through gene amplification
predicts aggressive malignant disease. However, not all N-
Myc overexpressing tumors present with unfavorable histol-
ogy or fail treatment [31]. Furthermore, in a transgenic
mouse model, N-Myc overexpression produced clonal NB-
like tumors after considerable latency, reflecting a require-
ment for other genetic alterations as second hits [32]. These
observations suggest that N-Myc expression alone in NB is
insufficient to bestow a malignant phenotype. Rather,
A.
Parental Line Transfected Clone/
Inoculum
No Tumor Tumor Latency
(days)
vector  1x107
vector  2x107
N-Myc  2x107
bcl-2  2x107
bcl-2/N-Myc 1x107 51-78
SH-EP1
bcl-2/N-Myc  2x107 43-54
vector  2x107
N-Myc 1x107 24-27
N-Myc 2x107 18-21
bcl-2  2x107 61
bcl-2/N-Myc  1x107 13-23
SK-N-AS
bcl-2/N-Myc  2x107 16-24
B.
Figure 4. (A ) Frequency plot of tumor formation in athymic mice. Mice were inoculated with ( 1 or 2 )107 cells and tumors determined by palpation. (B )
Representative micrograph of H and E stained tumor specimen (25 ) from SH-EP1 Bcl - 2 /N -Myc tumor highlighting biphasic phenotype.
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aggressive tumor behavior likely depends on other specific
gene products that act cooperatively with N-Myc.
Our data establishes that coexpression of Bcl -2 and N-
Myc in NB cells furthers the malignant phenotype. In vitro
growth in low serum or in soft agar is particularly dependent
on coexpression as the same dependency was observed for
both cell lines evaluated. Coexpression was necessary for
SH-EP1 cells to become tumorigenic in the xenograft model.
Conversely, in the SK-N-AS line single gene expression of
N-Myc or Bcl -2 was sufficient for tumor growth, revealing an
important difference between SH-EP1 and SK-N-AS cells
with respect to their ability to acquire malignant features. In
the SK-N-AS cells coexpression appears to increase
tumorigenicity above that achieved with either gene product
alone. Thus on the basis of the SK-N-AS results it appears
that coexpression of N-Myc and Bcl -2 is not always required
for NB tumorigenesis. It also must be recognized that our
results do not conclusively exclude the possibility that SH-
EP1 single gene transfectants can form tumors. For
example, tumors may have formed if inoculated cell number
was significantly increased or tumors may have formed at a
frequency below that detectable with the number of mice
used in this study. To summarize, coexpression convincingly
increased the malignant phenotype beyond that achieved
with either gene alone in SH-EP1 cells. Coexpression
appears to increase tumorigenicity in SK-N-AS cells
(particularly at the 1107 inoculum); however, larger sample
size would be necessary to conclude this definitively.
SK-N-AS cell survival in low serum is compromised by
N-Myc expression in the absence of Bcl -2. Mechanistically,
this finding may highlight one basis for the cooperativity
between these gene products. Studies with c-myc have
similarly revealed that its expression under conditions of
growth factor deprivation induces apoptosis [33] and that
Bcl -2 is able to rescue these cells from death [7–9]. Thus, it
appears cooperation between Bcl -2 and N-Myc emerges
from the ability of Bcl -2 to overcome the pro-apoptotic
action of N-Myc expression. These observations offer
further support for the hypothesis proposed by Cory et al.
[34] that synergy between oncogenes results from the ability
of one to counter the antioncogenic impulses of the other.
Despite extensive study, the mechanism underlying the
oncogenic activity of c-myc (and N-myc as well ) remains ill
defined. The activity of myc genes has been linked to
increased proliferation and cell cycle progression ( reviewed
in Cole and McMahon [35] ). Indeed the mechanism by
which c-myc induces apoptosis appears to be closely
associated with its effects on the cell cycle ( reviewed in
Thompson [36] ). In our system, N-Myc is likely providing
cells an increased proliferative capacity possibly through
transcriptional activation of cyclin Dl /bcl -1 as described for
c -myc [37]. Under low serum conditions, this proliferative
response may trigger apoptotic signals that are blocked
when Bcl-2 is coexpressed.
Multiple cellular processes must converge to allow
establishment and growth of a tumor within an animal. Not
surprisingly properties in addition to proliferative capacity
and resistance to apoptosis are required. Paramount among
these is the tumor cell’s ability to recruit and support new
blood vessels, termed angiogenesis. In human tumors N-
myc amplification has been associated with an increased
vascular index that independently predicts poor outcome
[38]. Tumor microvessel counts were higher in SK-N-AS
coexpressing tumors compared to SH-EP1 coexpressing
tumors. This difference corresponds with the increased
tumorigenicity of the SK-N-AS Bcl-2 /N-Myc cells. Com-
parison of the vascularity in SK-N-AS coexpressing tumors
to SK-N-AS tumors expressing Bcl -2 or N-Myc alone
reveals that coexpression results in increased tumor blood
vessels. This response provides support for the concept of
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Figure 5. Microvessel counts of tumors. Two unique SH-EP1 and SK -N -AS transfected cell lines expressing N -Myc and Bcl - 2 each formed tumors in nude mice.
At sacrifice, tumors were resected and microvessels quantified by CD31 expression. Data presented as mean vessels / 10 HPF.
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cooperative action of these oncogenes in the SK-N-AS cell
model. Rat cornea angiogenic responses to conditioned
media revealed that expression of either Bcl -2 or N-Myc
increased angiogenic activity from control and that coex-
pression led to a further additive increase. These results
demonstrate angiogenic activity results from the expression
of either N-Myc or Bcl -2 through independent processes
that appear to not require the presence of the other gene
product.
NB tumor growth is supported by autocrine and paracrine
stimulation through IGF- IR [25,26]. Inhibition of IGF- IR
expression blocks NB tumor behavior in mice [39]. By
binding to IGF-IR, IGF- I induces morphologic changes that
are associated with migration and chemotaxis of NB cells
[27] and protects NB cells from apoptosis [40–42]. N-Myc
overexpression in NB cells leads to increased expression of
several components of the IGF system including IGF-II,
IGF- IR, IGFBP-2, and IGFBP-4 [43]. In a reciprocal
fashion IGF-I itself induces N-myc mRNA and protein
expression [44]. The mutual interdependence of these gene
products prompted these authors to suggest a hypothesis
whereby IGF-IR and N-Myc upregulate each other. In this
situation, a positive feedback loop would likely contribute to
aberrant cell behavior and tumorigenicity.
Because the IGF ligands signal through IGF- IR, we
sought to determine whether the differences in the tumori-
genic phenotype exhibited by the SH-EP1 and SK-N-AS
Bcl-2/N-Myc–expressing lines were related to differences
in IGF-IR expression. SH-EP1 cells express very little IGF-
IR and no IGF- I or IGF-II ligands [42]. SK-N-AS cells
express both IGF-IR and IGF-II, which support autonomous
growth of these cells in culture [45]. In the current study,
Figure 6. Neovascular response from conditioned medium derived from cultured SH-EP1 and SK -N -AS transfectants in the rat corneal implant assay. (A )
Quantification of microvessels by pixel counts showing mean and standard deviation of three separate experiments. Photomicrographs of the response following
treatment with conditioned medium from (B ) SK -N -AS Bcl - 2 /N -Myc and (C ) SK -N -AS vector control cells.
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expression of either Bcl -2 or N-Myc slightly increases IGF-
IR expression in SH-EP1 cells. Dramatic increases in IGF-
IR resulted when both Bcl -2 and N-Myc were expressed. In
contrast, Bcl -2 or N-Myc overexpression alone increased
IGF-IR in SK-N-AS cells. Thus, as is true for tumorigenicity,
Bcl -2 and N-Myc act cooperatively in SH-EP1 cells to
induce IGF-IR. In SK-N-AS cells, no evidence is seen for
cooperative induction of this receptor. In our results, all
tumor- forming cell lines expressed IGF-IR. This finding
begins to provide evidence that IGF- IR expression is
important in NB tumorigenesis. Further characterization of
additional NB cell lines with respect to IGF- IR expression
and tumorigenicity would be helpful to determine if indeed
IGF-IR expression is necessary for tumor growth.
In summary, our studies demonstrate Bcl -2 cooperates
with N-Myc to influence the growth characteristics and
tumorigenicity of NB cells. The coexpression of Bcl -2 and N-
Myc influences the vascularity of tumors and together they
enhance the angiogenic response in vitro. It is possible that
these findings are related to changes in growth factor
responses resulting through the upregulation of IGF-IR.
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